Skip to content
Peptigraph home

VIP Dosage: Doses Studied, Units and Chart

What doses of VIP have been used in published research, how they convert to syringe units, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureVasoactive intestinal peptideUpdated
Doses studied
6 studies
with a stated dose, listed below
Frequency
Varies by study
as used in studies
Half-life
Not found
No published half-life found (PubMed search, 11 Oct 2026)

Doses used in published studies

Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.

Doses of VIP used in published studies
DoseFrequency and routeStudy typeSource
target 600, 1200 and 1800 pmol/kg on days 1 to 3daily 12-hour infusion · intravenous · 3 daysHuman RCTn = 461The Lancet. Respiratory medicine 2023, PMID 37348524
not stated in abstractnot stated · intravenous · 3 daysHuman RCTn = 196Critical care medicine 2022, PMID 36044317
1, 3 and 6 pmol/kg/min15 minutes per dose · intravenous infusionHuman controlled trialThorax 1986, PMID 3787552
aviptadil with phentolamineself-administered · intracavernosal injectionHuman observationaln = 308The journal of sexual medicine 2025, PMID 40192471
100-microg single dosesingle dose · inhaledHuman uncontrolled trialn = 20The European respiratory journal 2008, PMID 18978135
400 pmol/kg/hrconstant · intravenous infusion · 100 minutesHuman uncontrolled trialn = 6The American journal of cardiology 1987, PMID 3687785

Before anyone considers it

  • VIP is not FDA approved for any use.
  • Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
  • Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
  • People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.

Intravenous aviptadil in COVID-19 respiratory failure

In the TESICO trial in COVID-19 respiratory failure, intravenous aviptadil (the drug form of VIP) was given as a 12-hour infusion on 3 days, targeting 600, 1200 and 1800 pmol/kg on days 1, 2 and 3.[3]

Drugs@FDA lists no VIP product, so no US label gives an amount.[17]

Inhaled and injected amounts in other uses

In 20 patients with pulmonary hypertension, a single inhaled 100-microg dose of aviptadil caused a small, temporary pulmonary vasodilation.[7]

For refractory erectile dysfunction, aviptadil was combined with phentolamine as an intracavernosal injection. The abstract states no per-injection amount.[6]

Common questions

Is VIP FDA approved?

No. VIP is not FDA approved for any use.

What is the VIP peptide dosing?

It depends on the route. In pulmonary hypertension, 20 patients inhaled a single 100-microg dose of aviptadil.[7]

Is there a VIP peptide protocol or cycle?

None is sourced. Drugs@FDA lists no VIP product, and the studies here used intravenous, inhaled and intracavernosal routes for unrelated conditions.[17]

More on VIP

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.The Lancet. Respiratory medicine · 2023PMID 37348524Accessed 2 Oct 2026
  4. 4The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.Critical care medicine · 2022PMID 36044317Accessed 2 Oct 2026
  5. 5Effect of infused vasoactive intestinal peptide on airway function in normal subjects.Thorax · 1986PMID 3787552Accessed 2 Oct 2026
  6. 6Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction.The journal of sexual medicine · 2025PMID 40192471Accessed 2 Oct 2026
  7. 7Inhalation of vasoactive intestinal peptide in pulmonary hypertension.The European respiratory journal · 2008PMID 18978135Accessed 2 Oct 2026
  8. 8Cardiovascular effects of vasoactive intestinal peptide in healthy subjects.The American journal of cardiology · 1987PMID 3687785Accessed 2 Oct 2026
  9. 9PubMed search: aviptadil[tiab] (30 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: aviptadil[tiab] AND (randomized[tiab] OR "clinical trial"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab] OR "vasoactive intestinal polypeptide"[tiab]) AND (randomized[tiab] OR trial[tiab] OR patients[tiab]) (1509 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (70 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: "vasoactive intestinal peptide"[tiab] AND (CIRS[tiab] OR "inflammatory response syndrome"[tiab] OR mycotoxin*[tiab] OR "water-damaged"[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: "vasoactive intestinal peptide"[tiab] AND ("clinical trial"[pt] OR randomized[tiab]) AND (inhal*[tiab] OR intranasal[tiab] OR sarcoid*[tiab] OR "pulmonary hypertension"[tiab] OR ARDS[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: aviptadil[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  16. 16PubMed search: (aviptadil[tiab] OR "vasoactive intestinal peptide"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR tolerab*[tiab] OR toxicity[tiab]) AND (humans[mh]) (94 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  17. 17Drugs@FDA (openFDA) search: active ingredient "vasoactive intestinal peptide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.